Irreversible opiate agonists and antagonists. IV. Analgesic actions of 14-hydroxydihydromorphinone hydrazones. 1988

C L Williams, and R J Bodnar, and J E Clark, and E F Hahn, and T F Burks, and G W Pasternak
Cotzias Laboratory of Neuro-Oncology, Memorial Sloan-Kettering Cancer Center, New York.

Several phenylhydrazone derivatives of oxymorphone [phenylhydrazone and p-nitrophenylhydrazone (OxyPNPH)] as well as oxymorphonazine produce a wash-resistant inhibition of radiolabeled opioid binding, suggesting nonequilibrium binding to opiate receptors. All are agonists and, in an effort to correlate their prolonged inhibition of binding with their pharmacology, we examined their analgesic actions in vivo. Dose-response curves at 1 hr revealed similar potencies of oxymorphone and the derivatives, with the exception of OxyPNPH which was significantly less potent. After 10 hr, oxymorphone at doses up to 50 mg/kg did not demonstrate any effect. In contrast, OxyPNPH at 25 mg/kg elevated tail-flick latencies from 2 to over 8 sec after 10 hr. The 50-mg/kg dose elevated latencies to approximately 5 sec after 24 hr. Oxymorphonazine and oxymorphone phenylhydrazone also produced a prolonged analgesia, although not as effectively as OxyPNPH. The prolonged analgesic actions of OxyPNPH were highly dependent upon a critical period of 2 to 3 h immediately after injection. Blockade of receptors during this period with naloxone prevented analgesia at all time points examined. If the long duration of action of OxyPNPH resulted simply from a long half-life and persistent-free compound within the brain, analgesia should have returned by 8 hr, at which time naloxone has been eliminated. The absence of analgesia 8 hr after both OxyPNPH and naloxone argues against simple pharmacokinetic mechanisms for the prolonged analgesia and is consistent with persistent receptor occupation. OxyPNPH (25 mg/kg) administered in vivo lowered radiolabeled opioid binding effectively in brain membranes despite extensive washing. OxyPNPH lowered mu1 binding by approximately 60% and mu2 binding by 35% whereas delta binding was not lowered significantly.

UI MeSH Term Description Entries
D008297 Male Males
D009270 Naloxone A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors. MRZ 2593-Br,MRZ-2593,Nalone,Naloxon Curamed,Naloxon-Ratiopharm,Naloxone Abello,Naloxone Hydrobromide,Naloxone Hydrochloride,Naloxone Hydrochloride Dihydride,Naloxone Hydrochloride, (5 beta,9 alpha,13 alpha,14 alpha)-Isomer,Naloxone, (5 beta,9 alpha,13 alpha,14 alpha)-Isomer,Narcan,Narcanti,Abello, Naloxone,Curamed, Naloxon,Dihydride, Naloxone Hydrochloride,Hydrobromide, Naloxone,Hydrochloride Dihydride, Naloxone,Hydrochloride, Naloxone,MRZ 2593,MRZ 2593 Br,MRZ 2593Br,MRZ2593,Naloxon Ratiopharm
D010111 Oxymorphone An opioid analgesic with actions and uses similar to those of MORPHINE, apart from an absence of cough suppressant activity. It is used in the treatment of moderate to severe pain, including pain in obstetrics. It may also be used as an adjunct to anesthesia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1092) Numorphan,Opana,Oxymorphone HCl,Oxymorphone Hydrochloride
D011957 Receptors, Opioid Cell membrane proteins that bind opioids and trigger intracellular changes which influence the behavior of cells. The endogenous ligands for opioid receptors in mammals include three families of peptides, the enkephalins, endorphins, and dynorphins. The receptor classes include mu, delta, and kappa receptors. Sigma receptors bind several psychoactive substances, including certain opioids, but their endogenous ligands are not known. Endorphin Receptors,Enkephalin Receptors,Narcotic Receptors,Opioid Receptors,Receptors, Endorphin,Receptors, Enkephalin,Receptors, Narcotic,Receptors, Opiate,Endorphin Receptor,Enkephalin Receptor,Normorphine Receptors,Opiate Receptor,Opiate Receptors,Opioid Receptor,Receptors, Normorphine,Receptors, beta-Endorphin,beta-Endorphin Receptor,Receptor, Endorphin,Receptor, Enkephalin,Receptor, Opiate,Receptor, Opioid,Receptor, beta-Endorphin,Receptors, beta Endorphin,beta Endorphin Receptor,beta-Endorphin Receptors
D004091 Hydromorphone An opioid analgesic made from MORPHINE and used mainly as an analgesic. It has a shorter duration of action than morphine. Dihydromorphinone,Hydromorphon,Dilaudid,Hydromorphone Hydrochloride,Laudacon,Palladone
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004743 Enkephalin, Leucine One of the endogenous pentapeptides with morphine-like activity. It differs from MET-ENKEPHALIN in the LEUCINE at position 5. Its first four amino acid sequence is identical to the tetrapeptide sequence at the N-terminal of BETA-ENDORPHIN. Leucine Enkephalin,5-Leucine Enkephalin,Leu(5)-Enkephalin,Leu-Enkephalin,5 Leucine Enkephalin,Enkephalin, 5-Leucine,Leu Enkephalin
D004745 Enkephalins One of the three major families of endogenous opioid peptides. The enkephalins are pentapeptides that are widespread in the central and peripheral nervous systems and in the adrenal medulla. Enkephalin
D006835 Hydrazones Compounds of the general formula R:N.NR2, as resulting from the action of hydrazines with aldehydes or ketones. (Grant & Hackh's Chemical Dictionary, 5th ed) Hydrazone
D000698 Analgesia Methods of PAIN relief that may be used with or in place of ANALGESICS. Analgesias

Related Publications

C L Williams, and R J Bodnar, and J E Clark, and E F Hahn, and T F Burks, and G W Pasternak
June 1980, Journal of medicinal chemistry,
C L Williams, and R J Bodnar, and J E Clark, and E F Hahn, and T F Burks, and G W Pasternak
May 1982, The Journal of neuroscience : the official journal of the Society for Neuroscience,
C L Williams, and R J Bodnar, and J E Clark, and E F Hahn, and T F Burks, and G W Pasternak
April 1983, Archives internationales de pharmacodynamie et de therapie,
C L Williams, and R J Bodnar, and J E Clark, and E F Hahn, and T F Burks, and G W Pasternak
December 1985, The Journal of pharmacology and experimental therapeutics,
C L Williams, and R J Bodnar, and J E Clark, and E F Hahn, and T F Burks, and G W Pasternak
January 1988, Life sciences,
C L Williams, and R J Bodnar, and J E Clark, and E F Hahn, and T F Burks, and G W Pasternak
May 1961, Toxicology and applied pharmacology,
C L Williams, and R J Bodnar, and J E Clark, and E F Hahn, and T F Burks, and G W Pasternak
December 1985, The Journal of pharmacology and experimental therapeutics,
C L Williams, and R J Bodnar, and J E Clark, and E F Hahn, and T F Burks, and G W Pasternak
August 1960, JAMA,
C L Williams, and R J Bodnar, and J E Clark, and E F Hahn, and T F Burks, and G W Pasternak
January 1993, Klinicheskaia khirurgiia,
C L Williams, and R J Bodnar, and J E Clark, and E F Hahn, and T F Burks, and G W Pasternak
June 1981, Physiology & behavior,
Copied contents to your clipboard!